Novo Nordisk lost billions in value because it failed to anticipate the risk posed by the introduction of its blockbuster ...
Pharmaceuticals that mimic hormones now provide effective medical tools to combat obesity. Their long-term effects on society remain to be seen.
From surgery to supplements, GLP-1 medications are radically evolving the beauty space. We unpack the latest innovations.
A pill version of Novo Nordisk A/S’s Ozempic failed to slow the progression of Alzheimer’s disease in a pair of long-shot ...
An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.
Novo Nordisk shares tumbled Monday morning after the Danish drugmaker posted the latest results from a drug trial.
Pharma major Novo Nordisk's stock plummeted a record 12.4% on 24 November after the Danish company's weight-loss pill Ozempic ...
Novo Nordisk A/S is slashing the cost of Ozempic for cash-paying patients after the diabetes shot became the poster child for high US drug prices. Patients can now get Ozempic for $499 a month - about ...
As competitive as the obesity drug market has become, Novo Nordisk's decision to slash the prices of its GLP-1 agonist drugs ...
The Financial Express on MSN
Novo Nordisk stock plunges to a four-year-low. Here is the reason behind the slump
Novo Nordisk shares plunge after semaglutide Alzheimer’s trial fails to meet its main goal, deepening pressure amid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback